To evaluate the importance of epidermal growth factor receptor (EGFR) protein overexpression and gene amplification in carcinogenesis of glottic cancer.
Epidermal growth factor receptor (EGFR), a 170 kDa transmembrane tyrosine kinase receptor, is a member of the EGFR family of cell surface receptors (1, 2) . The EGFR gene is located on the chromosome 7p12 (1) . The most researched family member is human epidermal growth factor receptor 2 (HER-2), which is the target of routine diagnostic and therapeutic protocols for breast cancer (3) . Even though less investigated than HER-2, EGFR protein is overexpressed in many solid head and neck tumors. It is connected with advanced and aggressive tumors and poor prognoses (1, 2, (4) (5) (6) .
The relation between protein overexpression and gene amplification still remains unclear. Although immunohistochemical (IHC) protein analysis of EGFR has been extensively researched, there is a lack of studies on gene amplification which seems to be important for new anti-EGFR therapies in some tumor types (2, (7) (8) (9) (10) (11) (12) (13) (14) . Two kinds of drugs have become the part of cancer therapy protocols: monoclonal antibodies that act against the ligand-binding domain and small molecules that inhibit the tyrosine-kinase activity of the receptor. They have been approved for use in some types of EGFR-dependent cancers (eg, colon, lung, and pancreas) (2, (7) (8) (9) (10) .
Understanding the EGFR signaling pathway and its implication in tumorigenesis is crucial in the selection of patients who could benefit from EGFR-targeted therapies. The selection of patients suitable for treatment is based on biomarkers that can predict the effectiveness of new therapeutic agents. Intensive studies of some type of lung cancers showed that gene amplification and mutations were more precise markers of treatment response than EGFR protein expression (8, 11, 12) . Research on colonic cancer demonstrated that EGFR gene amplification and protein overexpression were insufficient in predicting therapy response even though they were linked to prognosis. Patients demonstrating gene amplification showed better response to monoclonal antibody treatment in some studies, but downstream molecules such as v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue seem to be even more important in predicting response to therapy (9, 13, 14) .
Although EGFR protein overexpression has been studied in glottic lesions, there is a lack of information on gene amplification for this specific area. There is the need for further research of EGFR involvement in glottic carcinogenesis in order to optimize treatment protocols for this tumor type. Laryngeal cancer is the most prevalent malignant head and neck tumor in the male population in Croatia (15) , with one of the highest mortality rates among cancers of the head and neck region (15, 16) . The glottic region is the most common site of origin of laryngeal cancers. This cancer was chosen for research because the follow-up of atypical hyperplastic lesions of vocal cords and other precancerous formations is especially difficult and this cancer considerably affects patients' quality of life.
The aim of this study was to investigate the influence of EGFR protein overexpression and gene amplification on cancerogenesis of glottic cancer and their possible role in improvement of follow-up and treatment protocols of precancerous and cancerous glottic lesions.
PaTIeNTs aND MeTHoDs

Clinicopathological data
The research was performed on 145 biopsy/resection samples of glottic tissue from patients treated at the Department of Pathology and Otorhinolaryngology of the Clinical Hospital Center Rijeka between 2003 and 2008. The study was approved by the Ethics Committee of Clinical Hospital Center Rijeka and patients signed consent forms before enrolment. Based on classic pathohistological findings of hematoxylin-eosin slides, 3 main groups were formed: control patients (n = 38), patients with hyperplastic lesions (n = 46), and patients with cancerous lesions (n = 61). Hyperplastic lesions were graded according to the Gale-Kambič-Lenart Ljubljana classification (17) . Carcinomas were graded and staged according to the classification criteria of the World Health Organization and the tumor-node-metastasis system. Subsequently, they were divided into preinvasive (tumor in situ [Tis]) and invasive, and early (Tis-T 1 T 2 N 0 M 0 ) and advanced (all above T 2 N 0 M 0 ) carcinomas (18) .
The control group comprised patients treated for benign glottic lesions (nodule, polyp) who had simple hyperplasia as the greatest mucosal change. Hyperplastic lesions included 22 abnormal and 24 atypical hyperplastic lesions. All malignant cases were squamous cell carcinomas. Fortyseven invasive, 14 preinvasive, 32 early, and 27 advanced laryngeal carcinomas were analyzed.
There were 123 biopsy samples taken from male patients and 22 taken from female patients. The patients were aged from 38 to 81 years. Mean age of the control group was 51.5 ± 12.1, mean age of patients with precancerous lesions was 58.1 ± 11.8, and mean age of patients with glottic cancer was 56.9 ± 11.3 years. There were 78% smokers in the control group, 76% smokers among patients with precancerous lesions, and 70% of smokers among patients with glottic cancer.
Tissue microarray (TMa) construction
Hematoxylin-eosin stained sections of glottic mucosa were used to mark the areas with surface epithelial layers, avoiding areas of necrosis. Three tissue cores, each 1 mm in diameter, were placed in a recipient paraffin block using a manual tissue arrayer (Alphelys, Plaisir, France). The final TMA blocks contained 38 cores with tissue specimens that served as controls, 46 cores with hyperplastic lesions, and 61 cores of tumor samples. Normal liver tissue was used for slide orientation. Cores were spaced at intervals of 0.5 mm in the x-and y-axes. One section from each TMA block was stained with hematoxylin-eosin for morphological assessment. Serial sections were cut from TMA blocks for IHC staining. Five micrometers thick sections were placed on adhesive glass slides (Capillary Gap Microscope Slides, 75 μm, Code S2024, DakoCytomation, Glostrup, Denmark), left to dry overnight at 37°C, and stored in the dark at +4°C.
Immunohistochemical staining and evaluation of eGFR protein expression
Following deparaffinization in xylene and rehydration in alcohol, heat-induced epitope retrieval was achieved by immersing the slides in Tris-EDTA buffer (pH 9.0) and boiling them for 10 minutes in a water bath. Slides were allowed to cool over 45 minutes and then pre-incubated for 30 An analysis of EGFR protein expression was performed. Membranous and cytoplasmic staining was evaluated. Membranous staining (mEGFR) was divided into membrane high -continuous linear and membrane low -discontinuous staining. For positive cytoplasmic EGFR (cE-GFR) staining, an intense homogenous staining of the cytoplasm was necessary. There was no cEGFR without membrane staining. The cells were analyzed by a method adjusted to multilayer squamous epithelium, where changes occur in the layers. The basal zone was defined as cells with stromal contact, the superficial zone represented surface cells with applanated nuclei, while the suprabasal zone was defined as the transforming layer between them. Cell-counting was performed by 2 pathologists. The results were analyzed on automated image analyzer using Issa software (VamsTec, Zagreb, Croatia) by an experienced pathologist. Statistical analysis was performed counting all cells on 0.01 mm 2 in defined zones of control, hyperplastic, or cancerous tissue, and calculating the percentages of positive cells with mEGFR and cEGFR expressions.
Fluorescent in situ hybridization
After deparaffinization, the slides were pretreated with Paraffin Pretreatment Kit (Vysis, Downers Grove, IL, USA) using protease to digest proteins for 10 minutes. FISH was performed by applying EGFR probes (Vysis), LSI EGFR SpectrumOrange and CEP 7 SpectrumGreen for the respective centromeric region at chromosome 7. The LSI EGFR Dual Color probe hybridizes to the band region 7p12 in Spectrum Orange and the CEP 7 to the 7p11.1-q11, 1, D7Z1 locus in Spectrum Green. Denaturation of the probe mixture was performed at 95°C for 5 minutes in Thermobrite (Abbott Molecular Inc, Des Plaines, IL, USA) followed by overnight hybridization at 37°C. The following day, cover glass was removed and slides were washed in post-hybridization washing-buffer (Vysis) at 72°C for 2 minutes. After drying, DAPI (Vysis) was applied and slides were protected from light at -20°C until reading. Automated scanning, capture, and scoring of interphase FISH was analyzed by Cytovision System (Applied Imaging Corp., San Jose, CA, USA). EGFR gene amplification was defined as a ratio between EGFR gene (orange) and centromere (green) signals in tumor cell nuclei over 2.2 or the presence of EGFR gene clusters.
statistical analysis
Statistical analysis among 3 groups was carried out using Kruskal-Wallis or χ 2 tests as appropriate. For differences between single group pairs, the Mann-Whitney test was ap-plied. The level of statistical significance was set at P < 0.05. Data in tables are given as mean values ± standard deviations or percentages. Data were analyzed using SPSS, version 15.0, for Windows (SPSS Inc, Chicago, IL, USA).
ResulTs
Immunohistochemical evaluation of eGFR protein expression
The percentage of positive cells found by IHC analysis in distinct zones of multilayer squamous epithelium was compared within and between the groups (Figure 1-4) .
Although all 3 groups of patients had very similar mEGFR staining in the basal layer, hyperplastic and cancerous lesions group had an increase in high membranous staining vs simple hyperplasia of the control group.
The control group ( Figure 1A and 2) had mainly weak mEGFR staining in the suprabasal layer (67%). In dysplastic lesions compared with simple hyperplasia group, an increase in high mEGFR staining was found (P = 0.001; MannWhitney U-test), as well as between abnormal and atypical lesions (P = 0.035; Mann-Whitney U-test). Moreover, suprabasal mEGFR expression increased from weak to strong with the degree of atypia in hyperplastic lesions group. In abnormal hyperplastic lesions group ( Figure 1B and 3A) , 33 .2% of cells showed high mEGFR, as opposed to 51.1% in atypical lesions group ( Figure 1C and 3B ). Values were even higher in cancerous tissue, where 56.5% of cells had high mEGFR expression ( Figure 1D, 1E, and 4 ).
In the superficial layer, no high membranous staining was noticed in the control group, and the percentage of low mEGFR positive cells was lower than 1% (Figure 2 ). Low mEGFR was noticed in 18% of abnormal ( Figure 3A ) and up to 67% of atypical lesions ( Figure 3B ). In cancerous lesions, up to 61% of cells showed low and 20% high mEGFR staining (Figure 4 ). cEGFR staining in the control group was mainly basal and significantly lower than mEGFR staining (2.4%). Basal and suprabasal cEGFR expression was lowest in the control group, increased in abnormal and atypical hyperplastic lesions, and was highest in cancerous lesions group.
In simple hyperplasia and dysplastic lesions group, no superficial cytoplasmic staining was noticed; it appeared only in cancerous lesions group (1.3%).
In cancerous lesions group, an increase in mEGFR expression in the superficial layer was found with increased tumor grade. The number of negative cells in the suprabasal layer was significantly higher in gradus 1 than in gradus 2 (P = 0.023 Mann-Whitney U-test) and in gradus 1 than in gradus 3 (P = 0.031 Mann-Whitney U-test). The differences between cEGFR staining and grade were not observed (Kruskal-Wallis test). There was a borderline significant difference of mEGFR positive cells of the superficial layer between preinvasive and invasive tumors (P = 0.051; Mann-Whitney U-test). A significant difference between advanced and early staged tumors was found in highly positive basal cells (P = 0.044; Mann-Whitney U-test) and weakly positive superficial cells (P = 0.050; Mann-Whitney U-test). There were no differences in cEGFR staining between early and advanced tumor types (Mann-Whitney U-test).
EGFR protein expression did not show significant differences between non-smokers and smokers in precancerous and cancerous lesions. Smokers in the control group showed an increase in high mEGFR positive cells in the suprabasal transforming zone (P = 0.023; Mann-Whitney U-test). 
FIsH evaluation of eGFR gene amplification
FISH results were successfully obtained for 118 tissue samples. Failure to obtain results in 27 samples was mainly due to the loss of tissue materials during the TMA sectioning and hybridization procedure. EGFR gene amplification was found in 10 patients: 2 patients with precancerous lesions and 8 patients with laryngeal cancer. A significant difference in EGFR gene amplification was found between the analyzed groups. First, we evaluated 3 main groups (P = 0.031 between controls, hyperplastic lesions, and cancerous lesions; χ 2 test). For better insight in hyperplastic lesions, this group was divided into abnormal and atypical lesions subgroups (P = 0.045 between controls, abnormal hyperplastic lesions, atypical hyperplastic lesions, and cancerous lesions; χ 2 test, Table 1 ). All amplified lesions displayed 5 or more signals or clusters of EGFR gene ( Figure  5A and B).
There was no amplification in the control group ( Figure 5C ). In hyperplastic lesions group, amplification was detected in 2 cases of atypical hyperplasia (9.5%), one in atypical hyperplasia that developed into cancer within one month of follow-up, and the other in highly atypical dysplasia. The amplification was not detected in any case of abnormal hyperplasia.
In cancerous lesions group, EGFR gene amplification was found in 16% of cases. Some patients had previous biopsies. One of them presented with EGFR gene amplification in highly atypical hyperplasia prior to malignant transformation. In another patient, the amplification of the EGFR gene appeared in preinvasive cancer. Gene amplification was not connected either with tumor stage and grade or smoking habits (χ 2 test).
Comparison between eGFR protein expression and gene amplification
The 10 samples with EGFR gene amplification had higher IHC scores of cEGFR expression throughout all layers of squamous epithelium (basal layer P = 0.003; suprabasal layer P = 0.001; superficial layer P = 0.042; Mann-Whitney U-test). Increased values of high mEGFR staining were detected in suprabasal (P = 0.069; Mann-Whitney U-test) and superficial (P = 0.217; Mann-Whitney U-test) layers of 10 amplified samples, but they were not significantly increased.
In the group of precancerous lesion samples with and without gene amplification, there was no statistical difference in IHC EGFR protein expression.
In cancerous lesions, patients with and without EGFR gene amplification showed a significant difference in cEGFR staining in the basal (P = 0.003; Mann-Whitney U-test) and suprabasal layers (P = 0.002; Mann-Whitney U-test). Significant results are shown in Table 2 . Amplified cancerous lesions also showed increased high mEGFR staining in the suprabasal (P = 0.491; Mann-Whitney U-test) and superficial (P = 0.502; Mann-Whitney U-test) layers, although without significance.
DIsCussIoN
Reports about EGFR gene amplification in head and neck tumors are still lacking, especially in laryngeal cancerogenesis. Chromosome 7 aberrations have been found using FISH analysis of dysplastic and cancerous laryngeal tissue and connected with prognosis (19, 20) , but there has been no gene analysis. The significance of EGFR gene amplification as a possible mechanism for protein overexpression still remains unclear in glottic cancer because of the heterogeneous results of different studies (21) (22) (23) . The EGFR gene was discovered more than 20 years ago, but research has been stimulated only recently due to new anti-EGFR targeted therapeutic strategies (2, (7) (8) (9) (10) (11) (12) (13) (14) .
In this study, TMA technology enabled us to perform a uniform analysis of protein expression and gene amplification on the same study material (21, 22, 24) in order to obtain better insight into glottic tumor progression and the relation of these parameters with standard clinicopathological data.
Most studies on EGFR protein expression use semiquantitative IHC analysis, which is a relatively available and affordable technique, but subjective to the pathologist's experience. There is still a lack of technique standardization, staining intensity interpretation, and result evaluation, which sometimes causes difficulty in comparisons of results from different laboratories and authors. Some researchers consider only membranous staining as relevant, while others also take cytoplasmic staining into account and find it even more important for evaluation of tumor aggressiveness and prognosis (25) (26) (27) (28) (29) . Setting cut-off values is also difficult in evaluation of overexpression in a multilayer squamous epithelium like the glottic region, where changes occur in layers and cannot be analyzed as, for example, glandular tissue in well-researched breast cancers and pancreatic adenocarcinomas (3, 28) .
In this study, a more objective IHC evaluation of EGFR protein expression has been offered. The method is accurate, precise, and reproducible, and is more detailed and objective compared with the semiquantitative analysis, even though still dependent on the experience of the pathologist.
In our study, mEGFR expression showed a gradual change from negative to weak positive and strong positive throughout all layers, from control samples and hyperplastic lesions to cancerous tissue, with the changes being most striking in the suprabasal-transforming zone. These results indicate that high and low mEGFR staining can facilitate the differentiation between dysplastic lesions and simple hyperplasia and cancerous tissue, as well as between different degrees of atypia among the hyperplastic lesions. A gradual increase in cEGFR expression with an increase in dysplasia was also observed. Moreover, the study showed a significant correlation between protein expression and different levels of atypia in hyperplastic lesions, as well as aggressiveness (gradus) and stage (early vs advanced) in glottic cancer tissue, confirming EGFR as a possible predictor of clinical behavior and prognosis in glottic cancer.
In some reports, high levels of EGFR protein expression have been reported even in simple and abnormal hyperplastic lesions (25, 26, 29, 30) . In our study, high EGFR protein expression was also found in some control patients and patients with abnormal hyperplastic lesions; none of them showed gene amplification, which seems to be connected to the progression of highly atypical lesions into cancer tissue. Based on our results and available literature data (25, 26, (30) (31) (32) (33) , routine IHC analysis of EGFR in follow-up protocols of glottic lesions is suggested. IHC methodology is relatively simple and affordable, but needs standardization. This is why a more objective quantitative IHC assessment of EGFR protein levels was offered in this research. In cases where IHC of EGFR and classical pathohistological analysis are inconclusive, we suggest the detection of gene ampli- fication by FISH, which could improve the identification of lesions at high risk of cancer development. In this way, already genetically altered tissue, with high probabilities of cancer formation, could be diagnosed before it develops into cancer.
To the best of our knowledge and available literature data, we are the first to report results about EGFR gene amplification in precancerous lesions. EGFR gene amplification was found in high-risk atypical hyperplastic lesions in 2 cases. There was no EGFR gene amplification in simple or abnormal hyperplastic lesions. This indicates that EGFR gene amplification can facilitate differentiation of precancerous lesions with high malignant potential before they develop into glottic cancer. We find these results important and believe they could improve follow-up of hyperplastic lesions, prevention, and early detection of laryngeal cancer.
In cancerous lesions, EGFR gene amplification was found in 16% of the cases, which is in accordance with the few published studies on laryngeal cancer (21, 29, 34) . Some of these patients had previous biopsies. One patient displayed EGFR gene amplification in highly atypical hyperplasia prior to malignant transformation. In another patient, who showed no EGFR gene amplification in atypical hyperplasia, the amplification of the EGFR gene appeared in preinvasive cancer. Other patients showing gene amplification were diagnosed with glottic cancer on their first visit and information on EGFR gene status of their hyperplastic lesions is lacking. In this research, in already developed carcinomas, EGFR gene amplification was not connected with stage or grade. The results are similar to those of other authors, who found no difference in EGFR gene amplification and tumor stage (21) and grade (29, 34) . This indicates that gene amplification seems to be a genotype change that happens even before phenotype changes at levels of atypical hyperplastic and preinvasive cancerous lesions in some cancer types, acting more in pathogenesis than in progression of glottic cancer. Even though only a small percentage of EGFR protein overexpression could be explained by gene amplification, both were found to happen early in glottic carcinogenesis.
Comparing IHC and FISH results in our tumor samples, an increase in cytoplasmic, basal, and suprabasal EGFR protein levels in tumors showing EGFR gene amplification was noticed. The only previous study comparing EGFR at protein and gene level by IHC and chromogenic in situ hybridization on laryngeal tumors was performed by Tsiambas et al (29) . In contrast to our study, these authors did not observe any significant correlation between EGFR protein expression and gene amplification. Our findings in glottic cancer have yet to be confirmed in future trials. Further research is needed to evaluate the impact of cEGFR expression and gene amplification in glottic cancer, since some authors have found that cytoplasmic expression is connected with poor prognosis in some tumor types (ie, renal carcinoma and pancreatic adenocarcinoma) (27, 28) . Our research was limited to the evaluation of the glottic region and the strict relation between EGFR gene and protein expression, along with their correlation with classic pathohistological findings. EGRF gene mutations in laryngeal carcinogenesis and the analysis of nuclear EGFR are planned for future research.
In conclusion, our study demonstrated gene amplification as an early event in glottic cancerogenesis at the levels of high-risk atypical hyperplastic lesions and preinvasive carcinomas. This finding could improve glottic cancer prevention and early detection before genotype changes undergo tumor phenotype formation. An association was confirmed between mEGFR expression and gene amplification in glottic lesions, as well as a significant correlation between cEGFR staining and gene amplification in cancerous tissue. The implication of these findings in laryngeal carcinogenesis and the impact on prognosis and treatment have yet to be discovered. 
